[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369581-105":59,"doc-detail-369581-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","engineering-car-t-therapeutics-for-enhanced-solid-tumor-targeting","Engineering CAR-T Therapeutics for Enhanced Solid Tumor Targeting","","Cancer immunotherapy, particularly chimeric antigen receptor (CAR)-T cell therapy, has achieved transformative outcomes in hematological cancers but shows limited efficacy in solid tumors, which represent over 90% of cancer cases. Solid tumors impose major barriers, including antigen heterogeneity and a complex tumor microenvironment. This review surveys experimental and computational engineering strategies, such as protein engineering with machine learning, and discusses challenges in T cell delivery and in vivo reprogramming. It also highlights engineered organoid systems as high-fidelity validation platforms to improve CAR discovery and future therapeutic effectiveness.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/engineering-car-t-therapeutics-for-enhanced-solid-tumor-targeting/369581/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/engineering-car-t-therapeutics-for-enhanced-solid-tumor-targeting/369581.png","ImageObject",300,407,{"name":92,"@type":93},"วิน","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does CAR-T therapy work better in hematological cancers than in solid tumors?","Question",{"text":112,"@type":113},"Hematological cancers show stronger clinical responses, while solid tumors face limited CAR-T efficacy due to barriers such as antigen heterogeneity and the complex tumor microenvironment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are the main obstacles solid tumors present to CAR-T therapeutics?",{"text":117,"@type":113},"Solid tumors exhibit antigen distribution heterogeneity across patients and complex tumor microenvironments, including genomically and transcriptomically varied tumor and stromal/immune components.",{"name":119,"@type":110,"acceptedAnswer":120},"How do engineered organoid systems contribute to CAR-T development?",{"text":121,"@type":113},"Engineered organoid systems provide high-fidelity in vitro models that mimic the human tumor microenvironment, supporting validation and improving CAR discovery.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369581,1790294748,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","REVIEW   \n[www.advmat.de](www.advmat.de)  \nEngineering CAR-T Therapeutics for Enhanced Solid Tumor Targeting  \nDanqing Zhu,* Won Joon Kim, Hyunjin Lee, Xiaoping Bao,* and Pilnam Kim*  \nCancer immunotherapy, speciﬁcally Chimeric Antigen Receptor  \n(CAR)-T cell therapy, represents a signiﬁcant breakthrough in treating cancers. Despite its success in hematological cancers, CAR-T exhibits limited eﬃcacyin solid tumors, which account for more than 90% of all cancers. Solid tumors commonly present unique challenges, including antigen heterogeneity and complex tumor microenvironment (TME). To address these, eﬀorts are being made through improvements in CAR design and the development of advanced validation platforms. While eﬃcacy is limited, some solid tumor types, such as neuroblastoma and gastrointestinal cancers, have shown responsiveness to CAR-T therapy in recent clinical trials. In this review, it is ﬁrst examined both experimental and computational strategies, such as protein engineering coupled with machine learning, developed to enhance T cell speciﬁcity. The challengesand methods associated with T cell delivery and in vivo reprogramming in solid tumors is discussed. It is also explored the advancements in engineered organoid systems, which are emerging as high-ﬁdelity in vitro models that closely mimic the complex human TME and serve as a validation platform for CAR discovery. Collectively, these innovative engineering strategies  \noﬀer the potential to revolutionize the next generation of CAR-T therapy, ultimately paving the way for more eﬀective treatments in solid tumors.  \nsingle-chain variable fragment (scFv) or ligand-receptor interaction fragment, transmembrane, and intracellular domains for stimulating signaling pathways in T cells for activation (Figure 1) . CAR engineering aims to repurpose the natural signaling components of T cells to target antigens of cancer cells for speciﬁcity. However, current attempts to harness the power of engineered T cells mostly focus on treating hematological malignancies with limited efﬁcacy in other cancer types, especially solid tumor, which accounts for more than 90% of cancers. [2]  \nCompared with hematological cancers, solid tumors present unique obstacles to CAR-T therapeutics. The primary challenge is the heterogeneity of antigen distribution in cancer cells within solid tumors across patients. Tumor antigen heterogeneity developed through diverse clonal evolution patterns and complex tumor microenvironments (TMEs), both genomically and transcriptomically, vary signiﬁcantly across patients. [3,4] In addition, cellular  \n1. Introduction  \nCancer immunotherapy harnesses the potential of the innate immune system to combat the tumors. With a recently approved clinical product for the treatment of lymphoma,[1] CAR-T cell therapy has demonstrated transformative precision and eﬀective anti-tumor immunity. Conventional CAR designs consist of three essential elements, extracellular domain that consists of  \nheterogeneity is also important as it is associated with drug resistance and patient prognosis. [5] For example, cell types other than cancer cells constituting the TME, such as stromal cells like cancer-associated ﬁbroblasts,[6] vascular cells,[7] and immune cells like macrophages,[8] exhibit considerable diverse molecular subtypes. The clinical response of anticancer CAR-T therapeutics is mainly determined by antigen location, persistence, and downstream  \nD. Zhu, W. J. Kim  \nDepartment of Chemical and Biological Engineering, School of Engineering  \nThe Hong Kong University of Science and Technology (HKUST) Kowloon, Hong Kong SAR 999077, China  \nE-mail: [dqzhu@ust.hk](dqzhu@ust.hk)  \nThe ORCID identiﬁcation number(s) for the author(s) of this article can be found under [https://doi.org/10.1002/adma.202414882](https://doi.org/10.1002/adma.202414882)[ ](https://doi.org/10.1002/adma.202414882)© 2025 The Author(s). Advanced Materials published by Wiley-VCH GmbH. This is an open access","cbCaig7YdghpLnvg","https://ap.wps.com/l/cbCaig7YdghpLnvg","pdf",2866011,18,"English","# Introduction\n## CAR-T for solid tumors: rationale and limitations\n## Engineering strategies to enhance specificity\n## Delivery and in vivo reprogramming challenges\n## Engineered organoid systems for validation","[{\"question\":\"Why does CAR-T therapy work better in hematological cancers than in solid tumors?\",\"answer\":\"Hematological cancers show stronger clinical responses, while solid tumors face limited CAR-T efficacy due to barriers such as antigen heterogeneity and the complex tumor microenvironment.\"},{\"question\":\"What are the main obstacles solid tumors present to CAR-T therapeutics?\",\"answer\":\"Solid tumors exhibit antigen distribution heterogeneity across patients and complex tumor microenvironments, including genomically and transcriptomically varied tumor and stromal/immune components.\"},{\"question\":\"How do engineered organoid systems contribute to CAR-T development?\",\"answer\":\"Engineered organoid systems provide high-fidelity in vitro models that mimic the human tumor microenvironment, supporting validation and improving CAR discovery.\"}]","Engineering CAR-T Therapeutics for Enhanced Solid Tumor Targeting | PDF",1790183538,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df1d4b043c4c39f9365ca39eb27b1030.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02ae1260f203b81aa250994d0017a654.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5772ecdc6e4cf2417ddde3ae1998534a.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0dd1488ef70f9a9fa4b8c79321b6319.webp",980,1287]